Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma

NCT04557020 is registered in ClinicalTrials.gov with Jiangxi Provincial Cancer Hospital as lead sponsor.

NCT NCT04557020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04557020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma
Lead sponsor
Jiangxi Provincial Cancer Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
December 30, 2020
Completion date
March 1, 2026
Enrollment
200 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma